Skip to NavigationSkip to content


Clinigen becomes sole license holder of cancer drug Proleukin in $210m deal

Novartis has arranged to sell the remainder of its rights to its skin and lung cancer drug Proleukin (aldesleukin, recombinant interleukin-2) to Clinigen in a deal worth $210 million, it has emerged.

The agreement breaks down into an initial payment by Clinigen of $120 million, with $60 million to follow deferred over the 12 months following the deal’s completion. The rest will be paid in milestone payments, subject to sales performance.

Clinigen shares soar after $210m Novartis cancer drug deal

British company Clinigen has bought the rights to sell Novartis’ cancer drug Proleukin in the United States in a deal worth $210 million.

Clinigen, a growing speciality pharma group, already sells Proleukin outside of the US. Proleukin is used to treat metastatic kidney cancer and metastatic melanoma.

Clinigen will pay an initial sum of $120 million for the US rights alongside a further $60 million which will be differed for a year. The remaining $30 million will be paid dependent on the drug reaching certain sales milestones.

Eisai & Clinigen to bring breast cancer drug to South Africa

Eisai and Clinigen have formed a collaboration to deliver the former’s cancer treatment Halaven (eribulin) to women in South Africa suffering from advanced breast cancer.

Clinigen launches UK managed access program for Takeda’s ixazomib

Clinigen logo

Clinigen and Takeda have struck a deal to allow patients in the UK to access the multiple myeloma drug ixazomib through a managed access scheme.

Ixazomib is developed and manufactured by Takeda Pharmaceutical Company Limited. It has recently been approved by the FDA in the US, where it is marketed as Ninlaro, for use in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma, who have received at least one prior therapy.

Clinigen buys Idis for £225 million

Chief executive Peter George image
Clinigen chief executive Peter George

UK speciality pharma group Clinigen is paying £225 million to acquire the Surrey-based unlicensed supplier of medicines firm Idis.

Unlicensed medicines are those that are either already in clinical trials or approved in another market – and doctors can offer them to patients if they think they are the most appropriate treatment.

The companies say in a joint statement that this merger will create a “market leader in the ethical unlicensed supply of treatments”, to doctors and hospitals. 

Clinigen chief executive joins Ergomed board

Published on: 28/05/14

UK drug development
 services firm Ergomed has appointed Peter George to its
board as a non-executive director.


George has over 20 years’ experience in the
industry and is currently chief executive of speciality pharma services firm the Clinigen Group. 

Prior to Clinigen he was chief executive at Penn Pharma, and previously was
executive VP for Wolters Kluwer Health with responsibility for Europe and
Asia-Pacific regions.

Dominic Atkins joins Clinigen GAP in senior commercial role

Published on: 14/01/13

Pharma services company Clinigen Global Access Programs (Clinigen GAP) has appointed Dominic Atkins as global business development director.

In this senior commercial role reporting to Mark Corbett, Clinigen GAP’s vice-president, Atkins will be responsible for identifying, assessing and developing new international business opportunities across the pharmaceutical product lifecycle. He will be based near Basel in Switzerland.

Chief operating officer appointed to Clinigen’s services division

Published on: 19/01/12

Clinigen Group, a global specialty pharma services and products business, has appointed Shaun Chilton as its new chief operating officer of the group’s services division.

In this newly-created role, Chilton will have overall leadership responsibility for the division, incorporating two of Clinigen’s operations.

This includes Keats Healthcare, a clinical trial supply business (being re-branded as Clinigen CTS), and Clinigen GAP, a provider of early- and late-lifecycle prescription drugs. 

Mission Statement is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches